GTC Biotherapeutics (fka GTCB)

[ThomasS]

Related to my survey selection of NVS partnering with GTCB in the USA re ATRYN, and understanding that NVS/Sandoz has collaborations with MNTA:

"Our previously demonstrated ability to produce large volumes of monoclonal antibodies has led us into the follow-on biologics or FOBs [#msg-23650024] …and we have initiated the first program in this strategy with CD20 monoclonal antibody, the same target at Rituxan. This is under our collaboration with LFB. We have already identified a number of further potential products for introducing to this portfolio, each with already established multi-billion dollar markets."

Q: What is the possibility of MNTA characterizing the "potential product" and GTCB producing it?